GERI Study: Gathering Evidence and Real-World Insights in Osteoarthritis Management With Native (Undenatured) Type II Collagen

Background: Osteoarthritis (OA) is a progressive joint disorder and is increasingly prevalent in India. Conventional therapies offer symptomatic relief but do not address the underlying disease process. native (undenatured) type II collagen, a symptomatic slow-acting drug, has emerged as a promising adjunct in OA management due to its ability to modulate immune response and improve joint function. Objective: The gathering evidence and real-world insights (GERI) study aimed to assess the knowledge, attitudes, and practices (KAP) of Indian orthopedic healthcare providers (HCPs) regarding the clinical use of native (undenatured) type II collagen in OA management. Materials and Methods: A cross-sectional, questionnaire-based study was conducted among 416 orthopedic HCPs across India. It evaluated OA prevalence, treatment strategies, native (undenatured) type II collagen efficacy and safety, and quality-of-life outcomes using structured KAP questionnaires. Results: The majority of HCPs (95.1%) favored collagen supplementation, with 61% preferring native (undenatured) type II collagen. Over 74% recommended native (undenatured) type II collagen alongside pharmacologic therapy. Native (undenatured) type II collagen was most often initiated in early OA, with 60.2% reporting symptom improvement within 1–3 months. It was rated superior to glucosamine and chondroitin in adherence, efficacy, and tolerability. Additionally, 74.5% observed a reduction in nonsteroidal anti-inflammatory drugs use. Physical therapy and weight management were the most commonly recommended adjuncts. Conclusion: The GERI study highlights strong clinical acceptance of native (undenatured) type II collagen among Indian orthopedic HCPs as an effective and well-tolerated adjunct in OA management. Its early use, combined with lifestyle interventions, may offer sustainable benefits in improving patient outcomes and reducing reliance on conventional drugs. Clinical Trial Registration: ICEDH/20s24/11.